Pharmaceutical Mail. In 2020, Europe will continue to be the most attractive and competitive territory for biosimilars. However, the opportunities for generics in the mature markets (European and US) are diminishing as the number of small molecules that will lose their patent will be reduced compared to previous years. Generic manufacturers would find opportunities for growth in Asian markets, such as Japan and China, according to a new report published on the occasion of the chemical-pharmaceutical fair held last week in Barcelona CPhI Worldwide 2016 which has the collaboration of thirteen industry experts.

READ MORE